Cambridge Oncometrix’s project – a consortium made up of a three leading clinical partners UCLH, NHS Teaching Hospital Leeds and Norwich&Norfolk UHFT – has been awarded a million pounds of NHS funding to help diagnose prostate cancer.

Cambridge Oncometrix develops a non-invasive Prostate Liquid Biopsy test for risk stratification of men suspected of prostate cancer. The test measures the chemical element profile of semen and prostatic secretions. Prostate Liquid Biopsy is simple to administer and will improve treatment outcomes by diagnosing prostate cancer earlier.

The test will aid identification of men who will benefit from prostate biopsy and those who could safely forgo it, which will reduce the number of invasive biopsy procedures and post-biopsy complications, improve patients’ experience and aid efficient use of NHS resources.

Phase I of the project is already completed; biomarkers of prostate cancer in semen were shown to be detectable by technology.

The new funding for Phase II will be targeted towards clinical validation of the test and establishing an ISO and CLIA-certified centralised diagnostic laboratory, which will serve hospitals and GP in UK and EU.

About the SBRI Healthcare award

SBRI Healthcare is an NHS England initiative, led by the Academic Health Science Network (AHSN), who aim to promote UK economic growth while addressing unmet health needs and enhancing the take up of known best practice.

Four companies will share over £3.8 million development funding in the latest rounds of the programme.

See the announcement on SBRI healthcare site:


SBRI Healthcare fast tracks cancer diagnostic inventions with £3.8m funding